Pangaea Oncology, S.A.
PANG
Rank in Stocks
#22042
Pangaea Oncology, S.A. delivers essential medical services to cancer patients... Pangaea Oncology, S.A. delivers essential medical services to cancer patients across Spain and other European Union countries. Its extensive offerings encompass advanced molecular diagnostics, which include mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression profiling. The company is also active in clinical trials and provides in vitro drug profiling, employing techniques like MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing. Furthermore, Pangaea operates a specialized Dx platform for validating companion diagnostic platforms, benchmarking them against commercial alternatives, and offering bespoke research and development services to other diagnostic firms. A key focus also involves biomarker discovery, aiming to pinpoint novel targets for targeted therapies in their pre-clinical stages. Established in 2006, Pangaea Oncology, S.A. is headquartered in Barcelona, Spain.
Share Price
$1.64
Last synced: 2026-11-09
Market Cap
$58.90M
Change (1 day)
-0.67%
Change (1 year)
-19.21%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pangaea Oncology, S.A. (PANG)
Category
Healthcare
Operating Margin for Pangaea Oncology, S.A. (PANG)
Operating Margin as of November 2026 TTM: -25.06%
According to Pangaea Oncology, S.A.'s latest financial reports, its current operating margin (TTM) is -25.06%. At the end of 2025 the company had an operating margin of -25.06%.
Operating Margin history for Pangaea Oncology, S.A. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -25.06% | 0.00% |
| 2025 | -25.06% | -273.91% |
| 2024 | 14.41% | -142.01% |
| 2023 | -34.30% | -158.55% |
| 2022 | 58.58% | -605.87% |
| 2021 | -11.58% | -71.48% |
| 2020 | -40.60% | -71.91% |
| 2019 | -144.51% | 147.92% |
| 2018 | -58.29% | -43.58% |
| 2017 | -103.31% | 379.40% |
| 2016 | -21.55% | -56.90% |
| 2015 | -50.00% | -19.47% |
| 2014 | -62.09% | -1,013.09% |
| 2013 | 6.80% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 17.98% | -100.72% |
US
|
|
| 20.38% | -100.81% |
US
|
|
| 43.02% | -101.72% |
CN
|
|
| 32.03% | -101.28% |
US
|
|
| 22.23% | -100.89% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pangaea Oncology, S.A.'s operating margin
What is Pangaea Oncology, S.A.'s operating margin?
Pangaea Oncology, S.A.'s operating margin is -25.06%, as of Nov 2026.
What was Pangaea Oncology, S.A.'s operating margin in 2025?
In 2025, Pangaea Oncology, S.A.'s operating margin was -25.06%, compared with 14.41% in 2024.
How has Pangaea Oncology, S.A.'s operating margin changed since 2020?
From 2020 to 2025, Pangaea Oncology, S.A.'s operating margin was highest in 2022 (58.58%) and lowest in 2020 (-40.60%).
How does Pangaea Oncology, S.A.'s operating margin compare with similar companies?
Pangaea Oncology, S.A.'s operating margin (-25.06%) is lower than that of all 5 similar companies listed above. The highest among them is WuXi AppTec Co., Ltd., with 43.02%.